NASDAQ$IONS
Ionis Pharmaceuticals · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Ionis Pharmaceuticals reported its financial results for the fourth quarter and full year ended December 31, 2022.
Ionis Pharmaceuticals reported Q4 2022 total revenue of $152 million and a net loss of $52 million. The company's cash, cash equivalents, and short-term investments amounted to $1.987 billion. The company submitted the eplontersen NDA in the U.S.
- 2022 revenue was in line with expectations, reflecting revenue from numerous diverse sources.
- 2022 operating expenses increased as planned compared to the prior year, reflecting investments in pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen
- Further strengthened financial position with royalty monetization and sale and leaseback transactions worth up to $1.5 billion, including more than $700 million already received
- Submitted the eplontersen NDA in the U.S. for patients with polyneuropathy caused by hereditary TTR amyloidosis
Headline financials
Revenue & EPS history
Ionis · Revenue · Quarterly
$152M
Revenue by segment
Ionis · $118M total across 2 segments · Q4 2022
- SPINRAZA Royalties$67M-2.9%56.8%
- Collaborative Agreement Rev$51M—43.2%
Forward guidance
The Company’s 2023 guidance reflects its ability to earn substantial revenue from its commercial portfolio and partnered programs. It also reflects the Company’s commitment to investing in advancing its rich late-stage pipeline and preparing to commercialize its near-term commercial opportunities, eplontersen, olezarsen and donidalorsen, while maintaining a healthy balance sheet to continue investing for future growth.
Tailwinds
- Revenue >$575 million
- Operating expenses on a non-GAAP basis ~$970 - $995 million
- Net operating loss on a non-GAAP basis <$425 million
- Cash, cash equivalents and short-term investments ~$2.0 billion
- Continue to advance our innovative pipeline and achieve commercial readiness for eplontersen, olezarsen and donidalorsen.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2022
+0.2%
Avg return
Earnings day
+1.9%
Avg return
5 days after
+1.2%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+30.2%
Q3 2016
Best reaction
-13.5%
Q3 2011
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +5.1% | +6.6% | |
| Q4 2025 | -5.3% | -4.1% | -15.6% | |
| Q3 2025 | -2.3% | +0.1% | +12.5% | |
| Q1 2025 | +3.0% | +12.9% | +12.4% | |
| Q4 2024 | -0.4% | -0.2% | +3.0% | |
| Q3 2024 | -0.9% | +0.2% | -1.8% | |
| Q2 2024 | -0.7% | -4.9% | -3.6% | |
| Q1 2024 | -5.0% | -7.6% | -5.7% | |
| Q4 2023 | -0.8% | +3.9% | -3.7% | |
| Q3 2023 | +4.3% | +5.4% | +14.1% | |
| Q2 2023 | +0.7% | +0.8% | +4.2% | |
| Q1 2023 | +1.3% | -1.0% | +17.5% | |
| Q4 2022 | -4.0% | -5.3% | -11.2% | |
| Q3 2022 | +7.6% | +4.2% | -11.2% | |
| Q2 2022 | +0.9% | -3.5% | -3.2% | |
| Q1 2022 | -1.2% | -17.6% | -6.1% | |
| Q4 2021 | +3.4% | +10.9% | +19.3% | |
| Q3 2021 | +5.0% | +5.8% | -20.0% | |
| Q2 2021 | +4.2% | +2.0% | +4.5% | |
| Q1 2021 | -11.1% | -13.7% | -17.7% | |
| Q4 2020 | -4.7% | -3.6% | -23.4% | |
| Q3 2020 | +3.7% | +6.6% | +9.0% | |
| Q2 2020 | -4.6% | -8.7% | -6.1% | |
| Q1 2020 | -7.7% | -2.7% | -0.3% | |
| Q4 2019 | -3.6% | -5.4% | -10.7% | |
| Q3 2019 | +1.8% | +4.2% | +18.8% | |
| Q2 2019 | +6.6% | +6.2% | -3.6% | |
| Q1 2019 | +0.9% | -2.8% | -7.2% | |
| Q4 2018 | +15.2% | +14.4% | +31.7% | |
| Q3 2018 | +5.4% | -0.0% | +8.8% | |
| Q2 2018 | +4.4% | +11.6% | +1.9% | |
| Q1 2018 | +7.4% | +3.7% | +12.9% | |
| Q4 2017 | +2.8% | -4.7% | -14.2% | |
| Q3 2017 | +0.9% | +3.0% | -0.6% | |
| Q2 2017 | -8.6% | -11.0% | +7.4% | |
| Q1 2017 | -2.6% | +3.9% | +10.3% | |
| Q4 2016 | +5.4% | +16.6% | -13.8% | |
| Q3 2016 | +30.2% | +51.0% | +44.9% | |
| Q2 2016 | +0.1% | -2.5% | -14.1% | |
| Q1 2016 | -8.7% | — | — | |
| Q4 2015 | -4.6% | — | — | |
| Q3 2015 | +14.8% | — | — | |
| Q2 2015 | +1.0% | — | — | |
| Q1 2015 | +1.2% | — | — | |
| Q4 2014 | -0.8% | — | — | |
| Q3 2014 | +4.4% | — | — | |
| Q2 2014 | +6.3% | — | — | |
| Q1 2014 | -6.5% | — | — | |
| Q4 2013 | -9.7% | — | — | |
| Q3 2013 | -6.1% | — | — | |
| Q2 2013 | -4.2% | — | — | |
| Q1 2013 | -12.4% | — | — | |
| Q4 2012 | +7.6% | — | — | |
| Q3 2012 | -7.0% | — | — | |
| Q2 2012 | +3.9% | — | — | |
| Q1 2012 | +7.6% | — | — | |
| Q4 2011 | +2.8% | — | — | |
| Q3 2011 | -13.5% | — | — | |
| Q2 2011 | -8.2% | — | — | |
| Q1 2010 | -2.7% | — | — | |
| Q1 2011 | +2.8% | — | — | |
| Q4 2008 | -1.6% | — | — | |
| Q4 2010 | -1.6% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2010 | +2.5% | — | — | |
| Q4 2009 | -3.8% | — | — | |
| Q2 2010 | -3.8% | — | — | |
| Q2 2009 | -3.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro